Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented on the U.S. Food and Drug Administration's response to a citizen petition questioning the approval criteria for a generic Lovenox® (enoxaparin sodium) injection and its subsequent approval of another generic filer's Abbreviated New Drug Application (ANDA)...
Posted: 2010-07-27 03:00:00
More from this author:
Multiple Sclerosis: What Part Do Relapses Play In Severe Disability?
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Multiple Sclerosis Relapses and Severe Disability
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis.
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Stress, Fear, Anxiety and MS
From the Web > About.com Multiple Sclerosis: Most Popular Article
From the Web > About.com Multiple Sclerosis: Most Popular Article
Puusepp's sign—Clinical significance of a forgotten pyramidal sign
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Related Articles:
FDA Advisory Committee Recommends Approval for Fampridine in MS
From the Web > MedWorm: Multiple Sclerosis
Fampridine-SR likely to receive FDA approval with REMS/black box label
From the Web > MS Trust Recent Story List
MS Trust comments on CCSVI research
From the Web > MedWorm: Multiple Sclerosis
FDA Rejects Approval of MS Drug
From the Web > MedWorm: Multiple Sclerosis
Bayer wins Chinese approval for multiple sclerosis drug
From the Web > MedWorm: Multiple Sclerosis
